Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia

Auris Nasus Larynx

Volumn 26, Issue 3, 1999, Pages 317-330

  Izawa, Hidemi ^a   Yonemitsu, Nobuhisa ^a   Shin, Takemoto ^a   Sugihara, Hajime ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Immunohistochemistry; Laryngeal carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CELL LOSS; CELL PROLIFERATION; DYSPLASIA; FEMALE; GENE EXPRESSION; HUMAN; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LARYNGEAL NEOPLASMS; LARYNX; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032967950     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0385-8146(99)00005-X     Document Type: Article

References (54)

1. Younish-Rouach E., Resnitzky D., Lotem J. et al. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
2. Greenblatt M.S., Bennett W.P., Hollstein M. et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.[Review] [288 refs]. Cancer Res. 54:1994;4855-4878.
3. Bennett W.P. p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity, and colon.[Review] [109 refs]. Cancer Detect Prev. 19:1995;503-511.
4. Ziegler A., Jonason A.S., Leffell D.J. et al. Sunburn and p53 in the onset of skin cancer. Nature. 372:1994;773-776.
5. Crosthwaite N., Teale D., Franklin C. et al. p53 protein expression in malignant, pre-malignant and non-malignant lesions of the lip. J. Clin. Pathol. 49:1996;648-653.
6. Wagata T., Shibagaki I., Imamura M. et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 53:1993;846-850.
7. Kastan M.B., Zhan Q., el-Deiry W.S. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
8. Cross S.M., Sanchez C.A., Morgan C.A. et al. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
9. Todd D., Yang G., Brown R.W. et al. Apoptosis in renal cell carcinoma. detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum. Pathol. 27:1996;1012-1017.
10. Hashimoto S., Koji T., Kohara N. et al. Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchows Arch. 431:1997;241-248.
11. Aihara M., Scardino P.T., Truong L.D. et al. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 75:1995;522-529.
12. Baretton G.B., Diebold J., Christoforis G. et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 77:1996;255-264.
13. Tsujimoto Y., Finger L.R., Yunis J. et al. Cloning of the chromosome breakpoint of the neoplastic B cell with the t(14:18) chromosome translocation. Science. 226:1984;1097-1099.
14. Wang Y., Szekely L., Okan I. et al. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 8:1993;3427-3431.
15. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
16. Miyashita T., Krajewski S., Krajewska M. et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
17. Mitry R.R., Sarraf C.E., Wu C.G. et al. Wild-type p53 induces apoptosis in Hep3B through up-regulation of bax expression. Lab. Invest. 77:1997;369-378.
18. Gavrieli Y., Shermen Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
19. Wang L.D., Shi S.T., Zhou Q. et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int. J. Cancer. 59:1994;514-519.
20. Krajewska M., Krajewski S., Epstein J.I. et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148:1996;1567-1576.
21. Kerr J.F., Winterford C.M., Harmon B.V. et al. Apoptosis. Its significance in cancer and cancer therapy [Review] [179 refs]. Cancer. 73:1994;2013-2026.
22. Cummings M.C., Winterford C.M., Walker N.I. Apoptosis [Review] [130 refs]. Am. J. Surg. Pathol. 21:1997;88-101.
23. Ohbu M., Saegusa M., Okayasu I. Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas. Differences between keratinizing and nonkeratinizing types. Virchows Arch. 427:1995;271-276.
24. Lebrun D.P., Warnke R.A., Cleary M.L. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am. J. Pathol. 142:1993;743-753.
25. de Jong D., Prins F.A., Mason D.Y. et al. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 54:1994;256-260.
26. Hockenbery D.M., Zutter M., Hickey W. et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA. 88:1991;6961-6965.
27. Sabourin J.C., Martin A., Baruch J. et al. bcl-2 expression in normal breast tissue during the menstrual cycle. Int. J. Cancer. 59:1994;1-6.
28. Lu Q.L., Elia G., Lucas S. et al. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer. 53:1993;29-35.
29. Mochón A., Esteban F., Concha A. et al. Expression of proto-oncogene bcl-2 in squamous cell carcinoma of the larynx. Acta Otorrinolaringol. Esp. 48:1997;15-20.
30. Spafford M.F., Koeppe J., Pan Z. et al. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 122:1996;627-632.
31. Pilotti S., Collini P., Rilke F. et al. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J. Pathol. 172:1994;337-342.
32. Pezzella F., Turley H., Kuzu I. et al. Bcl-2 protein in non-small-cell lung carcinoma. New Engl. J. Med. 329:1993;690-694.
33. Anton R.C., Brown R.W., Younes M. et al. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer. Analysis of 427 cases. Hum. Pathol. 28:1997;1079-1083.
34. Rao S.K., Krishna M., Woda B.A. et al. Immunohistochemical detection of bcl-2 protein in adenocarcinoma and non-neoplastic cellular compartments of the lung. Mod Pathol. 9:1996;555-559.
35. Kapucuoglu N., Losi L., Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch. 430:1997;17-22.
36. Joensuu H., Pylkkänen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Br. J. Cancer. 145:1994;1191-1198.
37. Silvestrini R., Veneroni S., Daidone M.G. et al. The Bcl-2 protein. a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86:1994;499-504.
38. Hurlimann J., Larrinaga B., Vala D.L. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 426:1995;163-168.
39. Gorczyca W., Markiewski M., Kram A. et al. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas. their correlation with ki-67 growth fraction. Virchows Arch. 426:1995;229-233.
40. Saegusa M., Takano Y., Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J. Cancer Res. Clin. Oncol. 121:1995;357-363.
41. Tahara E. Molecular mechanism of stomach carcinogenesis. J. Cancer Res. Clin. Oncol. 119:1993;265-272.
42. McDonnell T.J., Troncoso P., Brisbay S.M. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
43. Bubendorf L., Sauter G., Moch H. et al. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am. J. Pathol. 148:1996;1557-1565.
44. Mcdonnell T.J., Troncoso P., Brisbay S.M. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
45. Henriksen R., Wilander E., Erg K. Expression and prognostic significance of Bcl-2 in ovarian tumors. Br. J. Cancer. 72:1995;1324-1329.
46. Nakagawa K., Yamamura K., Maeda S. et al. bcl-2 expression in epidermal keratinocytic diseases. Cancer. 74:1994;1720-1724.
47. Yamada T., Ohyama H. Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int. J. Radiat. Biol. 53:1988;65-75.
48. Gao H., Wang L.D., Zhou Q. et al. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk population in Henan, China. Cancer Res. 54:1994;4342-4346.
49. Nagano T., Ueda M., Ichihashi M. Expression of p53 protein is an early event in ultraviolet light-induced cutaneous squamous cell carcinogenesis. Arch. Dermatol. 129:1993;1157-1161.
50. Kawasaki Y., Monden T., Morimoto H. et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am. J. Clin. Pathol. 97:1992;244-249.
51. Mosnier J.F., Perret A.G., Vindimian M. et al. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum. Arch. Pathol. Lab. Med. 120:1996;654-659.
52. Yamaguchi A., Makimoto K., Goi T. et al. Overexpression of p53 protein and proliferative activity in colorectal adenoma. Oncology. 51:1994;224-227.
53. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
54. Ohue M., Tomita N., Monden T. et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res. 54:1994;4798-4804.